Literature DB >> 12780523

Tumour-type-specific capillary endothelial cell stainability in malignant B-cell lymphomas using antibodies against CD31, CD34 and Factor VIII.

Klas Norrby1, Börje Ridell.   

Abstract

The microvessel density (MVD) was assessed in lymph nodes infiltrated by diffuse large B-cell lymphomas, mantle cell lymphomas, chronic lymphatic leukemia and follicular lymphomas, and in lymphadenitis. Serial sections of formalin-fixed and paraffin-embedded tissue were stained with antibodies against CD31, CD34 or Factor VIII. Using light microscopy and computerised image analysis, the number and size of individual immunostained vessel profiles within a preselected area size range corresponding to capillaries, postcapillary venules, small collecting venules and small arterioles were determined. A significantly larger number of vessels were registered following staining with anti-CD34 than with anti-CD31 or anti-Factor VIII. Moreover, among the smallest capillary-sized vessel profiles in all lesion types, there was a selective relative loss of stainability of anti-CD31 and anti-Factor VIII, resulting in a substantial total loss of visualised capillary-sized vessels compared with anti-CD34. In fact, the number of non-detected capillaries following staining with anti-CD31 and anti-Factor VIII was significantly tumour type specific. These findings influence how we evaluate MVD data in B-cell lymphomas and possibly also other tumour types, as well as data relating to capillary endothelium-related functional variables of proliferation, apoptosis and maturation when different double-labelling immunohistochemical techniques are used and different tumour types are analysed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12780523     DOI: 10.1034/j.1600-0463.2003.1110406.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  6 in total

1.  The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas.

Authors:  Jelena Jelicic; Milena Todorovic Balint; Maja Perunicic Jovanovic; Novica Boricic; Marjan Micev; Jelena Stojsic; Darko Antic; Bosko Andjelic; Jelena Bila; Bela Balint; Sonja Pavlovic; Biljana Mihaljevic
Journal:  Pathol Oncol Res       Date:  2016-01-11       Impact factor: 3.201

2.  Immunohistochemistry in the evaluation of neovascularization in tumor xenografts.

Authors:  D Wang; C R Stockard; L Harkins; P Lott; C Salih; K Yuan; D Buchsbaum; A Hashim; M Zayzafoon; R W Hardy; O Hameed; W Grizzle; G P Siegal
Journal:  Biotech Histochem       Date:  2008-06       Impact factor: 1.718

3.  Nanotherapy silencing the interleukin-8 gene produces regression of prostate cancer by inhibition of angiogenesis.

Authors:  Ravikumar Aalinkeel; Bindukumar Nair; Chih-Kuang Chen; Supriya D Mahajan; Jessica L Reynolds; Hanguang Zhang; Haotian Sun; Donald E Sykes; Kailash C Chadha; Steven G Turowski; Katelyn D Bothwell; Mukund Seshadri; Chong Cheng; Stanley A Schwartz
Journal:  Immunology       Date:  2016-08       Impact factor: 7.397

4.  Adenosine receptors in regulation of dendritic cell differentiation and function.

Authors:  Sergey V Novitskiy; Sergey Ryzhov; Rinat Zaynagetdinov; Anna E Goldstein; Yuhui Huang; Oleg Y Tikhomirov; Michael R Blackburn; Italo Biaggioni; David P Carbone; Igor Feoktistov; Mikhail M Dikov
Journal:  Blood       Date:  2008-06-17       Impact factor: 22.113

Review 5.  In vivo models of angiogenesis.

Authors:  K Norrby
Journal:  J Cell Mol Med       Date:  2006 Jul-Sep       Impact factor: 5.310

6.  A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.

Authors:  Long Wang; Kenneth N Holder; Avvaru N Suhasini; An-Ping Lin; Harshita Bhatnagar; Sang-Woo Kim; August W Moritz; Ricardo C T Aguiar
Journal:  Leukemia       Date:  2015-10-27       Impact factor: 11.528

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.